--- title: "Lilly's Retatrutide Hits 30%: The 13F Read on LLY vs Novo" type: news slug: eli-lilly-retatrutide-triumph-13f-ownership canonical_url: https://13finsight.com/news/eli-lilly-retatrutide-triumph-13f-ownership published_at: 2026-05-22T03:16:21.202Z updated_at: 2026-05-22T03:16:23.732Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 645 locale: en source: 13F Insight --- # Lilly's Retatrutide Hits 30%: The 13F Read on LLY vs Novo Eli Lilly (LLY) reported topline Phase 3 TRIUMPH-1 results on May 21, 2026 showing its triple-agonist retatrutide drove average weight loss of up to 30.3% — 28.3% (about 70 pounds) at the 12 mg dose versus 2.2% on placebo across 2,339 adults over 80 weeks, with an extension cohort reaching 30.3% over 104 weeks plus osteoarthritis pain relief (Lilly investor relations; PRNewswire). Retatrutide targets three metabolic hormones — GIP, GLP-1, and glucagon — and the result pushes the efficacy ceiling well past Lilly's own Zepbound (~21%) and Novo Nordisk's (NVO) Wegovy (~15%).The news peg is the readout. The angle our ownership data adds is that this print widens an institutional divergence that was already visible in the 13F record. The obesity-drug story has been a two-horse race, but the holder bases of the two horses look nothing alike — and retatrutide's 30% number is the kind of catalyst that forces the discretionary money still hedging between them to pick a side.Who actually owns the Lilly side of the tradeLilly's register has a feature no other mega-cap pharma shares: its single largest holder is not an index fund but Lilly Endowment, the founding philanthropic vehicle that has held the stock for generations and does not trade around clinical readouts. That permanent anchor sits atop the usual index complex — BlackRock, Vanguard, and State Street — with PNC Financial Services also in the top tier. The practical effect is that a large slice of Lilly's float is structurally immobile: the endowment will not sell into strength and the index funds hold to weight, which means the marginal price-setter is a comparatively thin sliver of active capital reacting to exactly this kind of data.Our active-holder screen flags 17 managers running genuine discretionary mandates in Lilly. Those are the names whose next 13F filings carry signal. A readout that extends the efficacy lead is the moment a benchmark-underweight active manager either capitulates and buys, or concludes the obesity premium is fully priced and steps aside. Because the immobile base is so large, even modest active buying moves the stock — and even modest active selling is a louder distribution signal than it would be in a more freely-floating name.The Novo divergence is the real tellThe cleaner read is relative. Retatrutide widens Lilly's lead precisely as Novo Nordisk's US-listed shares work through their own positioning reset. Watch the next filing cycle for managers who hold both LLY and NVO as a paired obesity-exposure bet: a 30% efficacy print is the catalyst to collapse that pair into a single-name Lilly position. If the 13Fs show paired holders rotating out of Novo and concentrating into Lilly, that is the institutional verdict that the triple agonist has changed the competitive structure — not just the marketing.The verifiable anchors are concrete: the 30.3% peak weight loss, the 28.3% result at 12 mg, the 2,339-patient TRIUMPH-1 enrollment, the 80-week primary and 104-week extension durations, and Lilly's guidance that further TRIUMPH program readouts arrive later in 2026. Those are filed, board-disclosed figures, not analyst projections. The next regulatory milestone — an FDA submission timeline for retatrutide in obesity — is the catalyst that converts trial efficacy into a commercial TAM, and it is the event the active holders are positioning ahead of now.What to watch nextThe signal is concentration into Lilly at the expense of paired Novo exposure. If active managers add to LLY while trimming NVO, the smart-money read is that retatrutide re-rates Lilly as the structural winner of the obesity duopoly and the lead is durable. If they take profits into the print — selling strength while the endowment and index funds sit immobile — it means the discretionary community views the obesity premium as fully captured. Either way the move shows up in the filings before the tape. Track the Lilly-versus-Novo positioning and the broader GLP-1 ownership shifts through the institutional signals feed. ## FAQ ### What did Eli Lilly's retatrutide TRIUMPH-1 trial show? On May 21, 2026, Lilly reported that retatrutide drove average weight loss of up to 30.3% in Phase 3 TRIUMPH-1 — 28.3% (about 70 pounds) at the 12 mg dose versus 2.2% on placebo across 2,339 adults over 80 weeks, with a 104-week extension cohort reaching 30.3% plus osteoarthritis pain relief. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon. ### How does retatrutide compare to Zepbound and Wegovy? Retatrutide's up-to-30.3% weight loss pushes the efficacy ceiling past Lilly's own Zepbound at roughly 21% and Novo Nordisk's Wegovy at roughly 15%. As a triple agonist hitting GIP, GLP-1, and glucagon, it adds a third hormonal pathway versus the dual and single mechanisms of the current market leaders, extending Lilly's lead in the obesity-drug race. ### Who are Eli Lilly's largest institutional holders? Lilly's single largest holder is Lilly Endowment, the founding philanthropic vehicle that holds for generations and does not trade around clinical readouts. The index complex of BlackRock, Vanguard, and State Street follows, with PNC Financial Services in the top tier. That large immobile base means a thin sliver of active capital sets the marginal price. ### What should investors watch after the retatrutide readout? Watch the next 13F filings for managers holding both Lilly and Novo Nordisk as a paired obesity bet. A 30% efficacy print is the catalyst to collapse that pair into a single-name Lilly position. Rotation out of Novo and concentration into Lilly would signal the institutional verdict that the triple agonist changed the competitive structure. The next FDA submission timeline is the catalyst active holders are positioning ahead of. --- Source: 13F Insight — https://13finsight.com/news/eli-lilly-retatrutide-triumph-13f-ownership Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-22T03:16:23.732Z